Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-NK019 in R/R B-cell NHL
NCT04887012Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR-NK019 in B-cell non-Hodgkin lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Incidence of dose limiting toxicity at 28 days and Overall Response Rate at 2 years. Status: unknown.
02
Drugs
CAR-NK019
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04887012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887012.